User:Mr. Ibrahem/Glatiramer acetate
 | |
| Clinical data | |
|---|---|
| Trade names | Copaxone,[1] Glatopa,[2] Brabio, others |
| Other names | Glatiramer acetate, copolymer 1, Cop-1 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603016 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | Peptides[3] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C25H45N5O13 |
| Molar mass | 623.657 g·mol−1 |
  (what is this?) (verify) | |
Glatiramer acetate, sold under the brand name Copaxone among others, is a medication used to treat multiple sclerosis.[6] Specifically it is used for relapsing forms of MS including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] It is given by injection under the skin.[6]
Common side effects include pain at the site of injection, rash, shortness of breath, and chest pain.[1] Other side effects may include flushing, anxiety, lipoatrophy, and liver problems.[1] While there is no clear harm with use in pregnancy, such use has not been well studied.[7] It is a mixture of different sized peptides that are composed of the four amino acids, namely glutamic acid, lysine, alanine, and tyrosine.[3] It is believed to be similar to myelin basic protein (MBP) and inactivate antibodies directed against it.[3]
Glatiramer acetate was approved for medical use in the United States in 1996.[6] It is on the World Health Organization's List of Essential Medicines.[8] In the United Kingdom 4 weeks of medication costs the NHS about £515 as of 2021.[9] In the United States this amount costs about 1,200 USD.[10]
References[edit]
- ^ a b c d e f g "Copaxone- glatiramer acetate injection, solution". DailyMed. 23 July 2020. Archived from the original on 31 October 2021. Retrieved 11 November 2020.
- ^ a b "Glatopa- glatiramer acetate injection, solution". DailyMed. 31 July 2020. Archived from the original on 17 November 2020. Retrieved 11 November 2020.
- ^ a b c Babaesfahani, A; Bajaj, T (January 2021). "Glatiramer". StatPearls. PMID 31082051.
- ^ "Brabio 20 mg/mL Solution for Injection, Pre-filled Syringe - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 17 November 2020. Retrieved 11 November 2020.
- ^ "Copaxone 20 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 29 September 2020. Archived from the original on 12 November 2020. Retrieved 11 November 2020.
- ^ a b c d "Glatiramer Monograph for Professionals". Drugs.com. Archived from the original on 27 November 2021. Retrieved 3 December 2021.
- ^ "Glatiramer Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2020. Retrieved 3 December 2021.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 898. ISBN 978-0857114105.
- ^ "Glatiramer Prices and Glatiramer Coupons - GoodRx". GoodRx. Retrieved 3 December 2021.